Replies to post #19129 on Lexaria Bioscience Corp (LEXX)

[all4weed]

Based on the write up one can only imagine the wide applications of LXRP's Lipid technology for delivery.

Nicotine/Tobacco industry $770b
CBD Infused edibles $50b (including Canada and US where applicable)
Pain medication - $800b
Merger with LP's.

The OS is just 70mil shares, even at $1.60 the mcap is just 100m.


Even if fraction of the above 3 industries revenue royalties go to LXRP, you can talk about $500m to $1b revenue in next 2 yrs if deals are made.

So that examples why the rush to get in now before it becomes a lot bigger and who know might even get listed to a better exchange than OTC.